Validated using a knockout cell line
Recombinant
RabMAb

Anti-TIF1 alpha antibody [EPR6102] (ab174287)

Overview

  • Product name
    Anti-TIF1 alpha antibody [EPR6102]
    See all TIF1 alpha primary antibodies
  • Description
    Rabbit monoclonal [EPR6102] to TIF1 alpha
  • Host species
    Rabbit
  • Tested applications
    Suitable for: WB, IHC-Pmore details
    Unsuitable for: Flow Cyt,ICC/IF or IP
  • Species reactivity
    Reacts with: Mouse, Human
    Does not react with: Rat
  • Immunogen

    Synthetic peptide within Human TIF1 alpha aa 400-500 (Cysteine residue). The exact sequence is proprietary.
    Database link: O15164

  • Positive control
    • WB: HAP1, HeLa, HEK293 and MCF7 cell lysates. IHC: Human colon tissue and Human endometrial carcinoma tissue.
  • General notes

     

     

    Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMab® patents

    This product is a recombinant rabbit monoclonal antibody.

Properties

Applications

Our Abpromise guarantee covers the use of ab174287 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
WB 1/1000 - 1/10000. Predicted molecular weight: 116 kDa.
IHC-P 1/50 - 1/100. Perform heat mediated antigen retrieval before commencing with IHC staining protocol.
  • Application notes
    Is unsuitable for Flow Cyt,ICC/IF or IP.
  • Target

    • Function
      Transcriptional coactivator that interacts with numerous nuclear receptors and coactivators and modulates the transcription of target genes. Interacts with chromatin depending on histone H3 modifications, having the highest affinity for histone H3 that is both unmodified at 'Lys-4' (H3K4me0) and acetylated at 'Lys-23' (H3K23ac). Has E3 protein-ubiquitin ligase activity. Promotes ubiquitination and proteasomal degradation of p53/TP53. Plays a role in the regulation of cell proliferation and apoptosis, at least in part via its effects on p53/TP53 levels. Up-regulates ligand-dependent transcription activation by AR, GCR/NR3C1, thyroid hormone receptor (TR) and ESR1. Modulates transcription activation by retinoic acid (RA) receptors, including RARA. Plays a role in regulating retinoic acid-dependent proliferation of hepatocytes.
    • Pathway
      Protein modification; protein ubiquitination.
    • Involvement in disease
      Defects in TRIM24 are a cause of thyroid papillary carcinoma (TPC) [MIM:188550]. TPC is a common tumor of the thyroid that typically arises as an irregular, solid or cystic mass from otherwise normal thyroid tissue. Papillary carcinomas are malignant neoplasm characterized by the formation of numerous, irregular, finger-like projections of fibrous stroma that is covered with a surface layer of neoplastic epithelial cells. Note=A chromosomal aberration involving TRIM24/TIF1 is found in thyroid papillary carcinomas. Translocation t(7;10)(q32;q11) with RET. The translocation generates the TRIM24/RET (PTC6) oncogene.
    • Sequence similarities
      Contains 2 B box-type zinc fingers.
      Contains 1 bromo domain.
      Contains 1 PHD-type zinc finger.
      Contains 1 RING-type zinc finger.
    • Post-translational
      modifications
      Phosphorylated upon DNA damage, probably by ATM or ATR.
      Sumoylated.
    • Cellular localization
      Nucleus. Cytoplasm. Colocalizes with sites of active transcription. Detected both in nucleus and cytoplasm in some breast cancer samples. Predominantly nuclear.
    • Information by UniProt
    • Database links
    • Alternative names
      • E3 ubiquitin protein ligase TRIM24 antibody
      • E3 ubiquitin-protein ligase Trim24 antibody
      • hTIF1 antibody
      • PTC6 antibody
      • RING finger protein 82 antibody
      • RNF82 antibody
      • TF1A antibody
      • TIF1 antibody
      • TIF1-alpha antibody
      • TIF1A antibody
      • TIF1A_HUMAN antibody
      • TIF1ALPHA antibody
      • Transcription intermediary factor 1-alpha antibody
      • Transcriptional intermediary factor 1 alpha antibody
      • Transcriptional intermediary factor 1 antibody
      • Trim24 antibody
      • Tripartite motif containing 24 antibody
      • Tripartite motif-containing protein 24 antibody
      see all

    Images

    • Lane 1: Wild-type HAP1 cell lysate (20 µg)
      Lane 2: TIF1 alpha knockout HAP1 cell lysate (20 µg)
      Lane 3: HeLa cell lysate (20 µg)
      Lane 4: HEK293 cell lysate (20 µg)

      Lanes 1 - 4: Merged signal (red and green). Green - ab174287 observed at 130 kDa. Red - loading control, ab8245, observed at 37 kDa.

      ab174287 was shown to specifically react with TIF1 alpha when TIF1 alpha knockout samples were used. Wild-type and TIF1 alpha knockout samples were subjected to SDS-PAGE. ab174287 and ab8245 (loading control to GAPDH) were diluted at 1/1000 and 1/10 000 respectively and incubated overnight at 4°C. Blots were developed with goat anti-rabbit IgG (H + L) and goat anti-mouse IgG (H + L) secondary antibodies at 1/10000 dilution for 1 hour at room temperature before imaging.

    • All lanes : Anti-TIF1 alpha antibody [EPR6102] (ab174287) at 1/1000 dilution

      Lane 1 : HeLa cell lysate
      Lane 2 : 293T cell lysate
      Lane 3 : MCF7 cell lysate

      Lysates/proteins at 10 µg per lane.

      Predicted band size: 116 kDa

    • Immunohistochemical analysis of paraffin-embedded Human colon tissue labeling TIF1-alpha with ab174287 at 1/50 dilution.

    • Immunohistochemical analysis of paraffin-embedded paraffin-embedded Human endometrial carcinoma tissue labeling TIF1-alpha using ab174287 at 1/50 dilution.

    References

    ab174287 has not yet been referenced specifically in any publications.

    Customer reviews and Q&As

    There are currently no Customer reviews or Questions for ab174287.
    Please use the links above to contact us or submit feedback about this product.

    Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"

    Sign up